Chinese animated blockbuster "Ne Zha 2" is expected to surpass 100 million U.S. dollars in overseas box office, setting a new high for Chinese films going abroad in the past 20 years, chairman of its major producer Enlight Media said on Sunday during the ongoing 27th Shanghai International Film Festival (SIFF).
"Ne Zha 2," released in January this year, has become a global success, captivating audiences worldwide with its unique take on Chinese mythology and visually stunning animation. It is a sequel to the 2019 animated hit "Ne Zha."
Wang Changtian, chairman of Beijing Enlight Media - also the film's major investor, said, "We now expect the final overseas box office to exceed 100 million U.S. dollars, making it the highest in the past 20 years. This means that after two decades, we have a new opportunity to re-enter the international market with purely domestic Chinese films."
Since its release on January 29, 2025, "Ne Zha 2" has grossed over 15.8 billion yuan (about 2.2 billion U.S. dollars).
The Chinese version with English subtitles has been distributed in regions such as Asia, North America, Europe, and Oceania. At the same time, the English dubbed version will also see a secondary overseas release.
In merchandise sales, the "Ne Zha" series has generated hundreds of billions of yuan so far, providing significant benefits across development, production, and sales.
Wang predicted that merchandise sales are highly likely to achieve over 100 billion yuan.
"Ne Zha 2" sets new high for overseas box office of Chinese films in 20 years
South China's Guangdong Province is accelerating its transformation into an international medical tourism hub, positioning itself as a destination for patients worldwide seeking affordable, high-quality care.
The push follows a joint initiative announced in late March by nine Chinese government departments, including the Ministry of Commerce, aimed at boosting spending by foreign tourists and enhancing exports of tourism services as part of broader efforts to expand the country's service sector.
Every day, some of the most complex surgeries are performed here. Li Zilun, deputy director of the division of vascular surgery at the First Affiliated Hospital of Sun Yat‑sen University, is among the doctors capable of carrying out these intricate procedures.
He recently completed surgery on a patient with an aortic aneurysm, a condition often described as a "time bomb" in the body’s main artery, increasingly common in aging societies around the globe. Li also specializes in highly difficult and pioneering procedures, including repairing leaks caused by failed grafts.
"This was a very challenging case. And then, we implanted the covered stent to eliminate the endoleak. Actually, the outcome was pretty good. The patient will be discharged today," said Li Zilun.
The ability to handle such complex cases -- combining international techniques with domestically produced devices -- is drawing patients from around the world to seek treatment. In addition, high safety standards and low costs are also major draws.
"Our government is encouraging innovation. So, lots of physicians -- including our vascular surgeons -- we are actively involved in the innovation that helps to increase the effectiveness and safety, and also bring down the cost," said Li.
This hospital is one of the first in Guangdong to be designated by the provincial health commission as a pilot site for building an international medical service hub.
The growing number of patients has pushed the hospital to explore new ways to transform every step -- from treatment to payment and everything in between -- into a seamless experience, reducing waiting times and delivering better care for patients.
"I think it's fast. When the patient come here for just about, I think, one week, you can solve the problem," said Xiao Haipeng, president of the First Affiliated Hospital of Sun Yat-sen University.
The hospital is also deepening its international cooperation with top-tier medical institutions, including those at Harvard University.
"Not just for China, for the whole globe, we are facing health care challenges -- emerging infectious disease and chronic, lung infectious diseases, and also the aging population, also the shortage of healthcare workforce," said Xiao.
In response to these challenges, China is promoting its own solutions, including aggressive innovation in artificial intelligence (AI)-driven workflows, while stepping up research and development investment and global engagement along the way.
"In recent years, the innovation in Western medicine is dramatically growing. An example of my hospital -- in the past few years, we have 140 innovations and seven of them are international leading innovations," said Xiao.
As global demand for medical tourism grows, China is positioning itself as a new destination. Official data shows that the number of foreign patients in Guangdong increased by 20 percent last year. Among them, the growth in inpatient admissions was even faster, rising by 76 percent.
Guangdong fast-tracks pilot for int'l medical service hub
